Kintara Therapeutics Stock Predictions

Healthcare > Biotechnology

Buy KTRA

*Your capital is at risk

$0.215

+0 (+0%)

At Close: Jan 16, 2025

Currently predicting for Fri, 5 Jun 2026

KTRA Prediction Chart

KTRA Predictions History

Latest community submissions for KTRA.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
Skydude	Jul 3, 2023	$4.20 +4.22%	$4.13	V	98.31%	1
Duckula	Jun 30, 2023	Bearish	$4.03	V	—	1
JS Pro	Oct 26, 2021	$0.88 -1.71%	$0.90	X	98.29%	0
AlexVel Pro	Oct 26, 2021	$0.88 -2.40%	$0.90	X	97.60%	0
Diamond Pro	Oct 26, 2021	$0.89 -0.81%	$0.90	X	99.19%	3
Diamond Pro	Oct 25, 2021	$0.89 +0.91%	$0.88	X	99.09%	2
AlexVel Pro	Oct 14, 2021	$0.98 +8.26%	$0.91	X	91.74%	1
JS Pro	Oct 14, 2021	$0.99 +8.82%	$0.91	X	91.18%	1
Diamond Pro	Oct 14, 2021	$0.98 +7.71%	$0.91	X	92.29%	1
RamboRex3000 Pro	Aug 11, 2021	$1.56 -0.32%	$1.56	X	99.68%	5

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for KTRA with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT KINTARA THERAPEUTICS INC.

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intri...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by